WB (FAQ Protocol), ELISA (FAQ Protocol), IP (FAQ Protocol)
Species reactivity
Reacts with: Human
Specificity
Human LRG1
Immunogen
Recombinant Human LRG1 Protein (Catalog#13371-H08H)
Preparation
Produced in rabbits immunized with purified, recombinant Human LRG1 (rh LRG1; Catalog#13371-H08H; AAH34389.1; Met1-Gln347). LRG1 specific IgG was purified by Human LRG1 affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A & Antigen Affinity
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
Anti-LRG1 rabbit polyclonal antibody at 1:500 dilution Lane A: HepG2 Whole Cell Lysate Lane B: 293T Whole Cell Lysate Lane C: HL60 Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:38 kDa Observed band size:38 kDa
Anti-LRG1 rabbit polyclonal antibody at 1:500 dilution Lane A: HepG2 Whole Cell Lysate Lane B: 293T Whole Cell Lysate Lane C: HL60 Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:38 kDa Observed band size:38 kDa
LRG1 (Leucine-Rich Alpha-2-Glycoprotein 1) is a Protein Coding gene. LRG1 belongs to the leucine-rich repeat (LRR) family. Members of this family are involved in protein-protein interaction, signal transduction, and cell adhesion and development. LRG1 is expressed during granulocyte differentiation. It contains 4 LIM zinc-binding domains and 1 Rho-GAP domain. LRG1 is involved in promoting neovascularization (new blood vessel growth) by causing a switch in transforming growth factor-beta (TGFbeta) signaling in endothelial cells. LRG1 binds to the accessory receptor endoglin and promotes signaling via the ALK1-Smad1/5/8 pathway. It may be a potential therapeutic target for the treatment of diseases where there is aberrant neovascularization. Diseases associated with LRG1 include Appendicitis and Normal Pressure Hydrocephalus.
Research Areas
Cardiac Stem Cell Markers
References
O Donnell LC. et al., 2002, J Leukoc Biol. 72 (3): 478-85.
Li X. et al., 2007, Neurosci Lett. 413 (2): 141-4.
Ramachandran P. et al., 2006, J Proteome Res. 5 (6): 1493-503.